Advertisement
DMAC vs GLSI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a StrongBuy and GLSI is a Hold.
DMAC in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 04, 2026
DMAC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 47 similar instances where the stock broke above the upper band. In 40 of the 47 cases the stock fell afterwards. This puts the odds of success at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for DMAC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DMAC as a result. In 77 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for DMAC turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 40 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 219 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 132 of 169 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.166) is normal, around the industry mean (3.498). P/E Ratio (-13.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
GLSI's Stochastic Oscillator descends into oversold zone
The Stochastic Oscillator for GLSI moved into oversold territory on November 13, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +12.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 212 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLSI as a result. In 78 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for GLSI turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
GLSI moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
GLSI broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.498). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DMAC | GLSI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 39 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 55 | |
P/E GROWTH RATING 1..100 | 82 | 55 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DMAC's Valuation (69) in the Biotechnology industry is in the same range as GLSI (94) in the null industry. This means that DMAC’s stock grew similarly to GLSI’s over the last 12 months.
DMAC's Profit vs Risk Rating (39) in the Biotechnology industry is somewhat better than the same rating for GLSI (100) in the null industry. This means that DMAC’s stock grew somewhat faster than GLSI’s over the last 12 months.
DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as GLSI (100) in the null industry. This means that DMAC’s stock grew similarly to GLSI’s over the last 12 months.
DMAC's Price Growth Rating (35) in the Biotechnology industry is in the same range as GLSI (55) in the null industry. This means that DMAC’s stock grew similarly to GLSI’s over the last 12 months.
GLSI's P/E Growth Rating (55) in the null industry is in the same range as DMAC (82) in the Biotechnology industry. This means that GLSI’s stock grew similarly to DMAC’s over the last 12 months.
| DMAC | GLSI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | N/A |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| Advances ODDS (%) | 5 days ago 85% | 6 days ago 80% |
| Declines ODDS (%) | 2 days ago 81% | 2 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DMAC’s FA Score shows that 0 FA rating(s) are green while GLSI’s FA Score has 0 green FA rating(s).
- DMAC’s FA Score: 0 green, 5 red.
- GLSI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DMAC’s TA Score shows that 4 TA indicator(s) are bullish while GLSI’s TA Score has 2 bullish TA indicator(s).
- DMAC’s TA Score: 4 bullish, 5 bearish.
- GLSI’s TA Score: 2 bullish, 7 bearish.
Price Growth
DMAC (@Biotechnology) experienced а -6.09% price change this week, while GLSI (@Biotechnology) price change was -1.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
DMAC is expected to report earnings on Mar 23, 2027.
GLSI is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DMAC and
Correlation & Price change
A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with ANNX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then ANNX could also see price increases.
| Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
|---|---|---|---|---|
| DMAC | 100% | -5.79% | ||
| ANNX - DMAC | 47% Loosely correlated | -1.26% | ||
| VIR - DMAC | 47% Loosely correlated | -17.82% | ||
| EDIT - DMAC | 46% Loosely correlated | +1.40% | ||
| SLDB - DMAC | 46% Loosely correlated | -2.29% | ||
| TSHA - DMAC | 45% Loosely correlated | -2.61% | ||
More | ||||
GLSI and
Correlation & Price change
A.I.dvisor indicates that over the last year, GLSI has been loosely correlated with IPSC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GLSI jumps, then IPSC could also see price increases.
| Ticker / NAME | Correlation To GLSI | 1D Price Change % | ||
|---|---|---|---|---|
| GLSI | 100% | -2.23% | ||
| IPSC - GLSI | 36% Loosely correlated | +1.23% | ||
| RXRX - GLSI | 35% Loosely correlated | -4.35% | ||
| ABUS - GLSI | 34% Loosely correlated | +1.49% | ||
| DMAC - GLSI | 34% Loosely correlated | -5.79% | ||
| RZLT - GLSI | 34% Loosely correlated | -5.56% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DVLU | 39.24 | 0.12 | +0.32% |
| First Trust Dorsey Wright Momentum & Value ETF (DVLU) | |||
| XMHQ | 120.09 | 0.17 | +0.14% |
| Invesco S&P MidCap Quality ETF (XMHQ) | |||
| THRV | 22.95 | 0.01 | +0.07% |
| Prospera Income ETF (THRV) | |||
| DFE | 74.72 | -0.04 | -0.06% |
| WisdomTree Europe SmallCap Dividend Fund (DFE) | |||
| BGY | 5.42 | -0.03 | -0.55% |
| BlackRock Enhanced International Dividend Trust | |||